tiprankstipranks
Trending News
More News >
Simcere Pharmaceutical Group Limited (HK:2096)
:2096
Hong Kong Market

Simcere Pharmaceutical Group Limited (2096) Stock Statistics & Valuation Metrics

Compare
4 Followers

Total Valuation

Simcere Pharmaceutical Group Limited has a market cap or net worth of HK$30.24B. The enterprise value is HK$26.64B.
Market CapHK$30.24B
Enterprise ValueHK$26.64B

Share Statistics

Simcere Pharmaceutical Group Limited has 2,474,697,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,474,697,500
Owned by Insiders
Owned by Institutions

Financial Efficiency

Simcere Pharmaceutical Group Limited’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 7.66%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)7.66%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee1.01M
Profits Per Employee124.53K
Employee Count6,584
Asset Turnover0.58
Inventory Turnover2.21

Valuation Ratios

The current PE Ratio of Simcere Pharmaceutical Group Limited is 22.99. Simcere Pharmaceutical Group Limited’s PEG ratio is -0.93.
PE Ratio22.99
PS Ratio0.00
PB Ratio3.76
Price to Fair Value2.39
Price to FCF39.59
Price to Operating Cash Flow19.78
PEG Ratio-0.93

Income Statement

In the last 12 months, Simcere Pharmaceutical Group Limited had revenue of 6.64B and earned 733.16M in profits. Earnings per share was 0.29.
Revenue6.64B
Gross Profit5.32B
Operating Income848.05M
Pretax Income819.88M
Net Income733.16M
EBITDA1.35B
Earnings Per Share (EPS)0.29

Cash Flow

In the last 12 months, operating cash flow was 862.66M and capital expenditures 0.00, giving a free cash flow of 862.66M billion.
Operating Cash Flow862.66M
Free Cash Flow862.66M
Free Cash Flow per Share0.35

Dividends & Yields

Simcere Pharmaceutical Group Limited pays an annual dividend of HK$0.171, resulting in a dividend yield of 1.44%
Dividend Per ShareHK$0.171
Dividend Yield1.44%
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.65
52-Week Price Change120.04%
50-Day Moving Average9.46
200-Day Moving Average7.50
Relative Strength Index (RSI)65.09
Average Volume (3m)14.95M

Important Dates

Simcere Pharmaceutical Group Limited upcoming earnings date is Mar 31, 2023, TBA Not Confirmed.
Last Earnings DateAug 31, 2022
Next Earnings DateMar 31, 2023
Ex-Dividend DateJun 18, 2025

Financial Position

Simcere Pharmaceutical Group Limited as a current ratio of 2.00, with Debt / Equity ratio of 21.14%
Current Ratio2.00
Quick Ratio1.79
Debt to Market Cap0.06
Net Debt to EBITDA-0.54
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Simcere Pharmaceutical Group Limited has paid 86.71M in taxes.
Income Tax86.71M
Effective Tax Rate0.11

Enterprise Valuation

Simcere Pharmaceutical Group Limited EV to EBITDA ratio is 11.94, with an EV/FCF ratio of 0.00.
EV to Sales2.43
EV to EBITDA11.94
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00

Balance Sheet

Simcere Pharmaceutical Group Limited has HK$1.94B in cash and marketable securities with ¥1.21B in debt, giving a net cash position of -HK$733.70M billion.
Cash & Marketable SecuritiesHK$1.94B
Total Debt¥1.21B
Net Cash-HK$733.70M
Net Cash Per Share-HK$0.30
Tangible Book Value Per ShareHK$2.33

Margins

Gross margin is 79.08%, with operating margin of 12.78%, and net profit margin of 11.05%.
Gross Margin79.08%
Operating Margin12.78%
Pretax Margin12.36%
Net Profit Margin11.05%
EBITDA Margin20.35%
EBIT Margin17.12%

Analyst Forecast

The average price target for Simcere Pharmaceutical Group Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart Score8
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis